Sign in
Active, not recruitingNo phase

Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain

Key facts

Who runs it
Case Western Reserve University
Where
Chicago and Cleveland, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
People taking part
60 people, planned
Started
6 Jun 2019
Expected to end
7 May 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Active Comparator: Active tDCS + Active TUS
  • Sham
Record updated
29 June 2026

Who can take part

Age
40 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Able to provide informed consent to participate in the study
  • Subjects between 40 to 80 years old
  • Having diabetic neuropathic pain, involving at least 1 foot, with existing pain for at least 6 months, and having pain on at least half the days in the past 6 months with an average of at least a 4 on a 0-10 VAS scale)
  • Having pain resistant to common analgesics and medications for first-line therapy of chronic pain such as Tylenol, Aspirin, Ibuprofen, Soma, Parafon Forte DCS, Zanaflex, Codeine, etc
  • Must have the ability to feel pain as self-reported

Who cannot take part

  • Contraindications to tDCS in conjunction with TUS, i.e. metallic implant in the brain or implanted brain medical devices
  • History of alcohol or drug abuse within the past 6 months as self-reported
  • History of neurological disorders as self-reported
  • History of unexplained fainting spells as self-reported
  • History of severe head injury resulting in more than a momentary loss of consciousness as self-reported
  • History of neurosurgery as self-reported
  • Subject is pregnant
  • Use of carbamazepine within the past 6 months as self-reported
  • Suffering from severe depression (with a PHQ 9 score of ≥ 10)
  • Unstable pain (defined as pain intensities that vary by more than 4 points on 0-10 VAS scale over the 1-week period of trial run-in)

Where in United States

  • Ciro Ramos EstebanezChicago, United States
  • University Hospitals Cleveland Medical Center/ Dahms Clinical Research UnitCleveland, United States

About the trial

What the trial wants to find out

The purpose of this study is to assess the effects of Transcranial Direct Current Stimulation (tDCS) in combination with Transcranial ultrasound (TUS) for the treatment of pain and functional limitations in subjects with Diabetic Neuropathic Pain.

The 2 groups in the trial

  • Active Comparator: Active tDCS + Active TUSExisting treatment, for comparison

    Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).

  • ShamSham treatment, for comparison

    Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimization of Non-Invasive Brain Stimulation for Diabetic Neuropathy
Record updated
29 June 2026